What is the best treatment for fluctuating Parkinson's disease: Continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Journal of Neural Transmission

Volumn 118, Issue 6, 2011, Pages 907-914

  Hilker, Rüdiger ^d   Antonini, Angelo ^a,b   Odin, Per ^c  

^a RCCS San Camillo Venice   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d NONE

Author keywords

Apomorphine; Deep brain stimulation; Duodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

BRAIN DEPTH STIMULATION; CONTINUOUS DOPAMINERGIC DRUG DELIVERY; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; HEMOLYTIC ANEMIA; HUMAN; KIDNEY DISEASE; MENTAL DISEASE; MINIPUMP; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS NODULE; SUBTHALAMIC NUCLEUS; SUBTHALAMIC NUCLEUS BRAIN DEPTH STIMULATION;

EID: 80051665922     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0555-8     Document Type: Review

References (80)

1. Alegret M, Valldeoriola F, Marti M, Pilleri M, Junque C, Rumia J et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 19:1463-1469 (Pubitemid 40104056)
2. Antonini A (2007) Continuous dopaminergic stimulation-from theory to clinical practice. Parkinsonism Relat Disord 13 Suppl: S24-S28 (Pubitemid 47454560)
3. Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 9:859-867
4. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149 (Pubitemid 47067225)
5. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 5:244-246 (Pubitemid 351347862)
6. Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P et al (2000) Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 55:1732-1734
7. Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM et al (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 62:76-84
8. Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8:67-81
9. Bowron A (2004) Practical considerations in the use of apomorphine injectable. Neurology 62:S32-S36 (Pubitemid 38419833)
10. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G et al (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59:932-934
11. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5:235-245 (Pubitemid 43238347)
12. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77:450-453
13. Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21:687-709 (Pubitemid 39273964)
14. Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M et al (2007) Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 68:1345-1355 (Pubitemid 46659085)
15. Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE et al (2006a) Deep brain stimulation: postoperative issues. Mov Disord 21(Suppl 14):S219-S237 (Pubitemid 44028283)
16. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K et al (2006b) A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908 (Pubitemid 44315982)
17. Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24:993-1000
18. Diamond A, Jankovic J (2005) The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry 76:1188-1193 (Pubitemid 41208365)
19. Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151-166 (Pubitemid 351787111)
20. Hagell P, Odin P (2001) Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 33:21-34-37-28
21. Herzog J, Volkmann J, Krack P, Kopper F, Potter M, Lorenz D et al (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 18:1332-1337 (Pubitemid 38263319)
22. Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M et al (2004) Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cerebr Blood Flow Metab 24:7-16 (Pubitemid 38021264)
23. Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T et al (2005) Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76:1217-1221 (Pubitemid 41208371)
24. Hjort N, Ostergaard K, Dupont E (2004) Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 19:196-199 (Pubitemid 38312703)
25. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468-1474
26. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ et al (1993) Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 8:165-170 (Pubitemid 23131637)
27. Kalbe E, Voges J, Weber T, Haarer M, Baudrexel S, Klein JC et al (2009) Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 72:42-49
28. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20:151-157 (Pubitemid 40361117)
29. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE (2003) Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 99:489-495 (Pubitemid 37040409)
30. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R et al (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21(Suppl 14):S290-S304 (Pubitemid 44028288)
31. Krack P, Kumar R, Ardouin C, Dowsey PL, McVicker JM, Benabid AL et al (2001) Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 16:867-875 (Pubitemid 36041188)
32. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349:1925-1934 (Pubitemid 37409709)
33. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20:262-265 (Pubitemid 16044214)
34. Lagrange E, Krack P, Moro E, Ardouin C, Van Blercom N, Chabardes S et al (2002) Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 59:1976-1978 (Pubitemid 36076577)
35. Lezcano E, Gomez-Esteban JC, Zarranz JJ, Lambarri I, Madoz P, Bilbao G et al (2004) Improvement in quality of life in patients with advanced Parkinson's disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol 11:451-454 (Pubitemid 39037030)
36. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E et al (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95
37. Lyons KE, Wilkinson SB, Overman J, Pahwa R (2004) Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 63:612-616 (Pubitemid 39100813)
38. Macia F, Perlemoine C, Coman I, Guehl D, Burbaud P, Cuny E et al (2004) Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 19:206-212 (Pubitemid 38312705)
39. Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17:1235-1241 (Pubitemid 36041337)
40. Meiler B, Andrich J, Muller T (2008) Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 23:145-146 (Pubitemid 351281236)
41. Menon R, Stacy M (2007) Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 8:1941-1950 (Pubitemid 47321525)
42. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804 (Pubitemid 35231256)
43. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F et al (2004) Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl (9): 291-296 (Pubitemid 38822878)
44. Neef C, van Laar T (1999) Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 37:257-271 (Pubitemid 29452757)
45. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 104:343-348 (Pubitemid 33107378)
46. Nutt JG (2007) Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 22:1-9 (Pubitemid 46382666)
47. Nyholm D, Aquilonius SM (2004) Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 27:245-256 (Pubitemid 39447222)
48. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C et al (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156-163 (Pubitemid 36676295)
49. Nyholm D, Jansson R, Willows T, Remahl IN (2005a) Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 65:1506-1507 (Pubitemid 41552798)
50. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R et al (2005b) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216-223
51. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31:63-73 (Pubitemid 351489331)
52. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5:677-687 (Pubitemid 44081890)
53. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI (2006) Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 5:578-588 (Pubitemid 43867425)
54. Piallat B, Benazzouz A, Benabid AL (1996) Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8:1408-1414 (Pubitemid 26239820)
55. Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow up. J Neurol Neurosurg Psychiatry 65:709-716 (Pubitemid 28486650)
56. Poewe WH, Wenning GK (1998) The natural history of Parkinson's disease. Ann Neurol 44:S1-S9
57. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L (1993) Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol 60:656-659
58. Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 2:412-415 (Pubitemid 12039838)
59. Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100:163-167 (Pubitemid 29376827)
60. Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, Obeso JA (2004) Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry 75:1382-1385 (Pubitemid 39279802)
61. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S et al (2005) Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128:2240-2249 (Pubitemid 41407964)
62. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE (2000) Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 123(Pt 10):2091-2108
63. Samanta J, Hauser RA (2007) Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 8:657-664 (Pubitemid 46547018)
64. Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 56:251-253
65. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144-1148
66. Stacy M (2004) Apomorphine: North American clinical experience. Neurology 62:S18-S21 (Pubitemid 38419830)
67. Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403-406 (Pubitemid 18047004)
68. Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E et al (1993) Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 60:653-655
69. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 22:93-94 (Pubitemid 32622278)
70. The Deep Brain Stimulations for Parkinson's Disease Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345:956-963
71. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 58:396-401 (Pubitemid 34150913)
72. Voges J, Waerzeggers Y, Maarouf M, Lehrke R, Koulousakis A, Lenartz D et al (2006) Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery-experiences from a single centre. J Neurol Neurosurg Psychiatry 77:868-872 (Pubitemid 44023183)
73. Voges J, Hilker R, Botzel K, Kiening KL, Kloss M, Kupsch A et al (2007) Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 22:1486-1489 (Pubitemid 47280638)
74. Voges J, Kiening K, Krauss JK, Nikkhah G, Vesper J (2009) Neurosurgical standards in deep brain stimulation: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt 80:666-672
75. Volkmann J (2007) Deep brain stimulation for Parkinson's disease. Parkinsonism Relat Disord 13(Suppl 3):S462-S465 (Pubitemid 351215287)
76. Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE (2005) Psychiatric symptoms following surgery for Parkinson's disease with an emphasis on subthalamic stimulation. Adv Neurol 96:130-147
77. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M et al (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 131:2720-2728
78. Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J et al (2007) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130:2129-2145 (Pubitemid 47236623)
79. Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W (1999) Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 80:545-548
80. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO et al (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 7:605-614